133 related articles for article (PubMed ID: 8317456)
1. Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
Musolino C; Grosso P; Alonci A; Allegra A; Orlando A; Cincotta M; Buda G; Squadrito G
Am J Hematol; 1993 May; 43(1):1-4. PubMed ID: 8317456
[TBL] [Abstract][Full Text] [Related]
2. Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response.
de Mel WC; Hoffbrand AV; Giles FJ; Goldstone AH; Mehta AB; Ganeshaguru K
Br J Haematol; 1990 Apr; 74(4):452-6. PubMed ID: 2346724
[TBL] [Abstract][Full Text] [Related]
3. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
4. Alpha-interferon receptors in malignant B-cells from patients with chronic lymphocytic leukemia: relation to induction of 2'-5'-oligoadenylate synthetase and blast transformation.
Ostlund L; Grandér D; Juliusson G; Robèrt KH; Lundgren E; Einhorn S
Cancer Res; 1989 Jun; 49(12):3425-30. PubMed ID: 2524252
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of interferon and 2'-deoxycoformycin on 2',5'-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic leukemia cells.
Triozzi PL; Avery KA; Grever MR; Kraut EH
J Interferon Res; 1990 Oct; 10(5):535-40. PubMed ID: 2273300
[TBL] [Abstract][Full Text] [Related]
6. Induction of intracellular and plasma 2',5'-oligoadenylate synthetase by pentostatin.
Ho AD; Klotzbücher A; Gross A; Dietz G; Mestan J; Jakobsen H; Hunstein W
Leukemia; 1992 Mar; 6(3):209-14. PubMed ID: 1564958
[TBL] [Abstract][Full Text] [Related]
7. 2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
Millar BC; Bell JB
Br J Cancer; 1995 Dec; 72(6):1525-30. PubMed ID: 8519671
[TBL] [Abstract][Full Text] [Related]
8. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
9. Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.
Moritz T; Weissmann B; Grünewald B; Hust H; Kummer G; Niederle N
Mol Biother; 1992 Jun; 4(2):97-102. PubMed ID: 1381190
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
Boussiotis VA; Pangalis GA
Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
[TBL] [Abstract][Full Text] [Related]
11. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
12. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
[TBL] [Abstract][Full Text] [Related]
13. Primary leukemia cells resistant to alpha-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3.
Xu B; Grandér D; Sangfelt O; Einhorn S
Blood; 1994 Sep; 84(6):1942-9. PubMed ID: 8080997
[TBL] [Abstract][Full Text] [Related]
14. 2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Oct; 26(5):603-10. PubMed ID: 1752391
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with cisplatin and interferon alpha-2b (INTRON-A) in patients with penile carcinoma. Analysis of 2'5' oligo (A) synthetase and circulating interferon.
Mouratidou D; Kortsaris AH; Andreadis C; Galaktidou G; Vakalikos I
Int J Biol Markers; 1996; 11(1):55-7. PubMed ID: 8740645
[No Abstract] [Full Text] [Related]
16. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
Rosenblum MG; Maxwell BL; Talpaz M; Kelleher PJ; McCredie KB; Gutterman JU
Cancer Res; 1986 Sep; 46(9):4848-52. PubMed ID: 2942242
[TBL] [Abstract][Full Text] [Related]
17. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
18. Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL.
Jewell AP; Yong KL; Worman CP; Tsakona CP; Giles FJ; Goldstone AH
Br J Haematol; 1994 Feb; 86(2):441-3. PubMed ID: 8199046
[TBL] [Abstract][Full Text] [Related]
19. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers for response to interferon therapy?
Bezares F; Kohan S; Sacerdote de Lustig E; Farías E; Murro H; Horisberger MA
J Interferon Cytokine Res; 1996 Jul; 16(7):501-5. PubMed ID: 8836914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
